BIO-key International, Inc. (BYKI.PK) announced that the company has been allowed its tenth “Biometric Identification Network Security,” even more growing its portfolio of intellectual property for advanced authentication employing fingerprint biometric technology.
Don’t Miss: Are These 5 TOP Stock Performers Overbought?
Concur Technologies, Inc. (NASDAQ:CNQR): Needham upped its price target for Concur after the company’s Q3 results and reported that management’s tone on the call was optimistic. The firm holds to a Buy rating on the stock.
Halozyme Therapeutics, Inc. (NASDAQ:HALO): Following Halozyme’s report that the FDA has issued a thorough response letter for HyQ for primary immunodeficiency disease, Oppenheimer believes that the worries can be addressed with preclinical data. The firm removed HyQ revenue from its model on Halozyme in an effort to stay conservative and reduced its target on the stock from $13 to $11 while holding to an Outperform rating.
Ellie Mae, Inc. (NYSE:ELLI): Needham elevated its price target for Ellie Mae after the company’s Q2 outcomes and maintains a Buy rating on the stock.
Mellanox Technologies, Ltd. (NASDAQ:MLNX): Barclays plans on Mellanox to benefit from Big Data growth to OEMs fueled by trends in storage and virtualization. Barclays thinks Mellanox will have $1 billion in revenues in mid-2014 and maintains its Overweight rating.
Don’t Miss: Did Electronic Arts Leave Facebook Hanging?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.